comparemela.com

Latest Breaking News On - Senhwa biosciences - Page 5 : comparemela.com

Senhwa s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations

Senhwa Biosciences receives ODD for Silmitasertib to treat Biliary Tract Cancer

Senhwa Biosciences has announced the receipt of Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for Silmitasertib, a highly selective inhibitor of casein kinase 2 (CK2) to treat patients with biliary tract cancer (BTC).

Senhwa s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer

Senhwa s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer

TAIPEI and SAN DIEGO, Jan. 20, 2022 /PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Silmitasertib, a highly selective inhibitor of casein kinase 2 (CK2) to treat patients.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.